Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DXC006 Combined With ICI or Platinum in SCLC
NCT07559929Phase 2Recruiting
- Sponsor
- Hangzhou DAC Biotech
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of DXC-006 in small cell lung cancer (SCLC), sponsored by Hangzhou DAC Biotech. Started Aug 2026; status: recruiting.
02
Drugs
DXC-006
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07559929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559929.